NASDAQ:IMRN Immuron (IMRN) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free IMRN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.22▼$2.3050-Day Range$4.80▼$5.6152-Week Range$1.92▼$28.99Volume6,208 shsAverage Volume4,939 shsMarket Capitalization$12.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesShort InterestTrendsStock AnalysisCompetitorsHeadlinesShort InterestTrends Get Immuron alerts: Email Address Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Immuron Stock (NASDAQ:IMRN)Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Read More Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… IMRN Stock News HeadlinesJune 5, 2024 | globenewswire.comImmuron CEO, Steven Lydeamore to present at the Emerging Growth ConferenceMay 31, 2024 | globenewswire.comImmuron Board ChangesMay 31, 2024 | globenewswire.comImmuron CEO Steven Lydeamore to present at Peak Sky HighMay 7, 2024 | globenewswire.comImmuron Limited to Present at the Emerging Growth ConferenceMay 3, 2024 | globenewswire.comImmuron Director ResignationApril 15, 2024 | finance.yahoo.comImmuron Limited (IMRN) Interactive Stock Chart - Yahoo FinanceApril 15, 2024 | globenewswire.comImmuron to host Live Virtual EventApril 10, 2024 | finanznachrichten.deImmuron Limited: Immuron Travelan sales continued strong growthApril 10, 2024 | msn.comImmuron gains after Travelan sales updateApril 10, 2024 | globenewswire.comImmuron Travelan® sales continued strong growthMarch 27, 2024 | ca.finance.yahoo.comImmuron Limited (IMRN) Latest Stock News & Headlines - Yahoo FinanceMarch 22, 2024 | investing.comImmuron Ltd ADR (IMRN)March 7, 2024 | msn.comImmuron surges after mid-stage data for antidiarrheal medMarch 7, 2024 | globenewswire.comImmuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the USMarch 7, 2024 | msn.comASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3February 22, 2024 | benzinga.comImmuron Stock (NASDAQ:IMRN) Dividends: History, Yield and DatesFebruary 21, 2024 | globenewswire.comImmuron Presentation Australian Biologics Festival 2024February 13, 2024 | finanznachrichten.deImmuron Limited: Immuron achieves record Travelan salesFebruary 13, 2024 | finance.yahoo.comImmuron achieves record Travelan® salesJanuary 16, 2024 | finanznachrichten.deImmuron Limited: Immuron achieves record half yearly Travelan salesJanuary 16, 2024 | finance.yahoo.comImmuron achieves record half yearly Travelan® salesJanuary 15, 2024 | msn.comASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, TravelanJanuary 15, 2024 | au.investing.comImmuron chalks up stellar half-year Travelan sales as travel returns to pre-pandemic levelsDecember 22, 2023 | finance.yahoo.comImmuron Clinical Trials UpdateDecember 4, 2023 | proactiveinvestors.comImmuron enrols first patients in Campylobacter Challenge clinical studySee More Headlines Receive IMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/10/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRN CUSIPN/A CIK1660046 Webwww.immuron.com.au Phone(138) 892-4854Fax6103 98227735EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.52 Quick Ratio7.79 Sales & Book Value Annual Sales$1.22 million Price / Sales10.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book0.97Miscellaneous Outstanding Shares5,700,000Free Float5,300,000Market Cap$12.88 million OptionableNot Optionable Beta1.34 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jerry Kanellos Ph.D. (Age 60)CEO & COO Comp: $189.27kMr. Peter Anastasiou (Age 61)Exec. Vice Chairman Comp: $29.02kMr. Phillip Allen Hains (Age 62)CFO & Company Sec. Mr. David LyonHead of MarketingDr. Dan Ruben Peres (Age 45)Chief Medical Officer Key CompetitorsKezar Life SciencesNASDAQ:KZRLexaria BioscienceNASDAQ:LEXXCASI PharmaceuticalsNASDAQ:CASIImmix BiopharmaNASDAQ:IMMXDURECTNASDAQ:DRRXView All Competitors IMRN Stock Analysis - Frequently Asked Questions Are investors shorting Immuron? Immuron saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 10,600 shares, a drop of 27.9% from the April 30th total of 14,700 shares. Based on an average daily volume of 876,000 shares, the days-to-cover ratio is currently 0.0 days. View Immuron's Short Interest. What other stocks do shareholders of Immuron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immuron investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), CRISPR Therapeutics (CRSP), Dynavax Technologies (DVAX), OPKO Health (OPK), AbbVie (ABBV) and Co-Diagnostics (CODX). When did Immuron IPO? Immuron (IMRN) raised $6 million in an initial public offering (IPO) on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager. This page (NASDAQ:IMRN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.